Graham Capital Management L.P. Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Graham Capital Management L.P. has acquired a new position in Illumina, Inc., purchasing 12,927 shares valued at approximately $1.03 million during Q1.
• Illumina recently reported an EPS of $1.19 for the latest quarter, exceeding analysts' expectations of $1.02, despite revenues of $1.06 billion falling short of the $1.12 billion forecast.
• Analyst ratings for Illumina reflect a mixed outlook, with six analysts rating it a "Buy", eleven as a "Hold", and two as a "Sell"; the average target price is set at $123.06.

Graham Capital Management L.P. acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 12,927 shares of the life sciences company's stock, valued at approximately $1,026,000.

Other hedge funds have also recently modified their holdings of the company. Moors & Cabot Inc. increased its stake in Illumina by 2.5% in the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after acquiring an additional 145 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in Illumina by 3.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after buying an additional 164 shares during the last quarter. Probity Advisors Inc. grew its holdings in shares of Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after acquiring an additional 224 shares during the period. Xponance Inc. lifted its position in Illumina by 1.0% during the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock valued at $2,123,000 after purchasing an additional 264 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of analyst reports. Piper Sandler dropped their target price on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Morgan Stanley boosted their target price on shares of Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Barclays upped their target price on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Daiwa America downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Finally, Robert W. Baird lifted their price objective on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of "Hold" and a consensus price target of $123.06.

Illumina Trading Down 0.6%

Shares of NASDAQ ILMN traded down $0.62 during mid-day trading on Monday, hitting $98.31. The company's stock had a trading volume of 676,660 shares, compared to its average volume of 2,273,403. The stock has a market cap of $15.11 billion, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 2.22 and a beta of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company's fifty day simple moving average is $99.63 and its 200-day simple moving average is $88.39. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.